Brookfield Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Brookfield Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,777	Closed	-$8.37M	–	519
2023 Q2	$8.37M	Buy	23,777 +22,614	+1,944%	+$7.62M	0.03%	185
2023 Q1	$366K	Buy	+1,163	New	+$349K	﹤0.01%	603
2022 Q3	–	Sell	-34,445	Closed	-$9.71M	–	778
2022 Q2	$9.71M	Buy	+34,445	New	+$9.22M	0.04%	154
2022 Q1	–	Sell	-42,697	Closed	-$9.38M	–	793
2021 Q4	$9.38M	Buy	42,697 +29,816	+231%	+$5.8M	0.04%	132
2021 Q3	$2.34M	Buy	12,881 +4,039	+46%	+$789K	0.01%	321
2021 Q2	$1.78M	Buy	+8,842	New	+$1.85M	0.01%	380

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brookfield Corp's VRTX Position: Q3 2023 in Review

Brookfield Corp sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 23,777 shares — an estimated $8.37M sold.

Brookfield Corp first reported a position in VRTX in Q2 2021 and held it in 6 quarters. The position peaked at $9.71M in Q2 2022. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Brookfield Corp reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Brookfield Corp sold 23,777 Vertex Pharmaceuticals shares in Q3 2023, an estimated $8.37M.
Brookfield Corp first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 6 quarters.
Brookfield Corp's Vertex Pharmaceuticals position peaked at $9.71M in Q2 2022.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.